Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

HRA Pharma launches ellaOne emergency contraception in Europe

Oct. 5, 2009

Amicus Therapeutics plans to initiate phase I AT-2220 study for Pompe disease

Oct. 5, 2009

Phase I data presented on MKC-253 in healthy subjects and type 2 diabetes patients

Oct. 5, 2009

rHuPH20 accelerates insulin absorption in patients with type 1 diabetes

Oct. 2, 2009

Orexigen Therapeutics reports results from phase IIb trial of Empatic for obesity

Oct. 2, 2009

Acrux reports results from phase III trial of Axiron in testosterone deficiency

Oct. 2, 2009

BioCryst initiates phase II study of PNP inhibitor BCX-4208 for treatment of gout

Oct. 2, 2009

Sosei submits NDA for emergency contraceptive pill NorLevo in Japan

Oct. 1, 2009

Vildagliptin analogue PKF-275-055 improves experimental diabetic neuropathy

Oct. 1, 2009

Snapshots: Recent clinical data on denosumab from the ASBMR meeting

Oct. 1, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...